# Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

> **NCT04126200** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 208 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin
- **DRUG:** GSK3174998
- **DRUG:** Feladilimab
- **DRUG:** Nirogacestat
- **DRUG:** Dostarlimab
- **DRUG:** Isatuximab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT04126200
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-07
- **Primary completion:** 2025-04-17
- **Final completion:** 2027-03-11
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126200, "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04126200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*